Bartosz Hudzik: Better Control, Similar Tolerability With Quadruple Therapy in Resistant Hypertension
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared a post on LinkedIn about a recent article by Stefano Taddei et al, published in European Society of Cardiology:
”Resistant hypertension is often treated as a dosing problem.
But what if it’s actually a strategy problem?
Patients with true resistant hypertension face markedly higher risks of stroke, heart failure, kidney disease, and death — yet many remain on prolonged triple therapy despite uncontrolled BP.
The Phase 3 QUADRO trial challenges that inertia.
Switching patients from standard triple therapy to the first full-dose quadruple single-pill combination (adding bisoprolol) delivered:
- −8 mmHg additional systolic BP reduction in just 8 weeks
- Confirmed improvement on 24-hour ambulatory monitoring
- No serious safety concerns
- A single pill instead of therapeutic escalation by fragmentation
In other words: better control, similar tolerability, potentially better adherence.
If resistant hypertension drives disproportionate cardiovascular risk, should we be escalating faster — and simplifying sooner?”
Title: Quadruple vs triple therapy for resistant hypertension: the QUADRO trial
Authors: Stefano Taddei, Krzysztof Narkiewicz, Stéphanie Bricout-Hennel, Parvoleta Petrova, Cécile Batailler, Roland Asmar
Read the Full Article on European Society of Cardiology․
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 17, 2026, 14:33Richard Keller: Efficacy and Safety of Enlicitide in High-Risk ASCVD Patients
-
Feb 17, 2026, 14:32Flora Peyvandi: Population Pharmacokinetics to Guide Tailored Surgical Dosing in Von Willebrand Disease
-
Feb 17, 2026, 13:54Wolfgang Miesbach: 43-Year Study Links Black Coffee to Reduced Dementia Risk
-
Feb 17, 2026, 09:04Mahesan Subramaniam: A Heart Attack Is a Long Story That Ends Fast
-
Feb 16, 2026, 15:44Lakmali Silva: Silva Lab Showcases Research at the Gordon Research Conference on Plasminogen and Extracellular Proteolysis
-
Feb 16, 2026, 15:36Heghine Khachatryan: Strengthening Maternal Resilience Against Postpartum Hemorrhage
-
Feb 16, 2026, 15:34Sevak Mirabyan: Advancing Cancer Care Through Knowledge, Collaboration, and Early Diagnosis in Armenia
-
Feb 16, 2026, 15:29Chokri Ben Lamine: Key Clinical Insights of Drug Induced Thrombocytopenia
-
Feb 16, 2026, 15:28Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety